About
About Baotou Dongbao Bio-Tech Co.,Ltd
Baotou Dongbao Bio-Tech Co.,Ltd engages in the design, research and development, production, and sale of gelatin and collagen in the People's Republic of China and internationally. It offers pharmaceutical gelation, food additives gelatin, and photographic gelatin; hydrolyzed collagen, collagen peptide, fish collagen peptide, and agglomerated collagen; and private label collagen and unflavored collagen jars. The company also provides organic fertilizers, water soluble fertilizers, and compound microbial fertilizers; and industrial grade calcium hydrogen phosphate and feed grade calcium hydrogen phosphate. In addition, it is involved in the research and development, production, and sale of biological organic fertilizers, as well as empty capsules, as well as sale of terminal collagen. The company's products have applications in thickener, stabilizer, emulsifier, softgel, confection, empty hard capsules, plasma substitute, powder, tablets, beverage, and capsules, as well as fertilizers, animal feeds, industrial fields, etc. Baotou Dongbao Bio-Tech Co.,Ltd was founded in 1960 and is based in Baotou, the People's Republic of China.
Research context
Baotou Dongbao Bio-Tech Co.,Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 6 months ago
Baotou Dongbao Bio-Tech Co.,Ltd is currently in a long term downtrend where the price is trading 2.3% below its 200 day moving average.
From a valuation standpoint, the stock is 28.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.9.
Baotou Dongbao Bio-Tech Co.,Ltd's total revenue rose by 5.7% to $114M since the same quarter in the previous year.
Its net income has dropped by 39.0% to $4M since the same quarter in the previous year.
Finally, its free cash flow grew by 5.8% to $-55M since the same quarter in the previous year.
Based on the above factors, Baotou Dongbao Bio-Tech Co.,Ltd gets an overall score of 3/5.